248 related articles for article (PubMed ID: 24564844)
1. Anemia and iron deficiency in COPD patients: prevalence and the effects of correction of the anemia with erythropoiesis stimulating agents and intravenous iron.
Silverberg DS; Mor R; Weu MT; Schwartz D; Schwartz IF; Chernin G
BMC Pulm Med; 2014 Feb; 14():24. PubMed ID: 24564844
[TBL] [Abstract][Full Text] [Related]
2. Oral sucrosomial iron versus intravenous iron in anemic cancer patients without iron deficiency receiving darbepoetin alfa: a pilot study.
Mafodda A; Giuffrida D; Prestifilippo A; Azzarello D; Giannicola R; Mare M; Maisano R
Support Care Cancer; 2017 Sep; 25(9):2779-2786. PubMed ID: 28391437
[TBL] [Abstract][Full Text] [Related]
3. A comprehensive vision for intravenous iron therapy.
Coyne DW
Am J Kidney Dis; 2008 Dec; 52(6 Suppl):S14-20. PubMed ID: 19010257
[TBL] [Abstract][Full Text] [Related]
4. Anemia management among hemodyalisis patients at the University Hospital in Puerto Rico.
Ocasio HE; Diaz H; Cangiano JL; Báez R; Suárez E
Bol Asoc Med P R; 2014; 106(2):9-12. PubMed ID: 25065044
[TBL] [Abstract][Full Text] [Related]
5. Prevalence of anemia and its impact on mortality in patients with acute exacerbation of chronic obstructive pulmonary disease in a developing country setting.
Rahimi-Rad MH; Sadighi T; Rabieepour M; Dinparast R; RahimiRad S
Pneumologia; 2015; 64(3):27-30. PubMed ID: 26738367
[TBL] [Abstract][Full Text] [Related]
6. Clinical and economic outcomes in Medicare beneficiaries with stage 3 or stage 4 chronic kidney disease and anemia: the role of intravenous iron therapy.
Knight TG; Ryan K; Schaefer CP; D'Sylva L; Durden ED
J Manag Care Pharm; 2010 Oct; 16(8):605-15. PubMed ID: 20866165
[TBL] [Abstract][Full Text] [Related]
7. The role of iron in the management of chemotherapy-induced anemia in cancer patients receiving erythropoiesis-stimulating agents.
Mhaskar R; Wao H; Miladinovic B; Kumar A; Djulbegovic B
Cochrane Database Syst Rev; 2016 Feb; 2(2):CD009624. PubMed ID: 26845108
[TBL] [Abstract][Full Text] [Related]
8. Challenge of effectively using erythropoiesis-stimulating agents and intravenous iron.
Kapoian T
Am J Kidney Dis; 2008 Dec; 52(6 Suppl):S21-8. PubMed ID: 19010258
[TBL] [Abstract][Full Text] [Related]
9. International Anemia Prevalence and Management in Peritoneal Dialysis Patients.
Perlman RL; Zhao J; Fuller DS; Bieber B; Li Y; Pisoni RL; Robinson BM; Johnson DW; Kawanishi H; Davies SJ; Schreiber MJ; Perl J
Perit Dial Int; 2019; 39(6):539-546. PubMed ID: 31582465
[No Abstract] [Full Text] [Related]
10. Ferric gluconate is highly efficacious in anemic hemodialysis patients with high serum ferritin and low transferrin saturation: results of the Dialysis Patients' Response to IV Iron with Elevated Ferritin (DRIVE) Study.
Coyne DW; Kapoian T; Suki W; Singh AK; Moran JE; Dahl NV; Rizkala AR;
J Am Soc Nephrol; 2007 Mar; 18(3):975-84. PubMed ID: 17267740
[TBL] [Abstract][Full Text] [Related]
11. Prevalence of hematinics deficiency amongst female students and its correction.
Mehta BC; Kabeer RM; Patel Y
Indian J Hematol Blood Transfus; 2007 Dec; 23(3-4):88-91. PubMed ID: 23100922
[TBL] [Abstract][Full Text] [Related]
12. 2008 Japanese Society for Dialysis Therapy: guidelines for renal anemia in chronic kidney disease.
Tsubakihara Y; Nishi S; Akiba T; Hirakata H; Iseki K; Kubota M; Kuriyama S; Komatsu Y; Suzuki M; Nakai S; Hattori M; Babazono T; Hiramatsu M; Yamamoto H; Bessho M; Akizawa T
Ther Apher Dial; 2010 Jun; 14(3):240-75. PubMed ID: 20609178
[TBL] [Abstract][Full Text] [Related]
13. Anemia in pediatric hemodialysis patients: results from the 2001 ESRD Clinical Performance Measures Project.
Frankenfield DL; Neu AM; Warady BA; Fivush BA; Johnson CA; Brem AS
Kidney Int; 2003 Sep; 64(3):1120-4. PubMed ID: 12911565
[TBL] [Abstract][Full Text] [Related]
14. Comparison of intravenous iron sucrose to oral iron in the treatment of anemic patients with chronic kidney disease not on dialysis.
Charytan C; Qunibi W; Bailie GR;
Nephron Clin Pract; 2005; 100(3):c55-62. PubMed ID: 15824508
[TBL] [Abstract][Full Text] [Related]
15. [Treatment of iron deficiency in predialysis state by low molecular weight iron dextran high doses intravenously].
Fievet P; Coppin M; Brazier F; Lefèvre M; Stephan R; Demontis R
Nephrol Ther; 2012 Feb; 8(1):41-6. PubMed ID: 21684231
[TBL] [Abstract][Full Text] [Related]
16. Achievement of renal anemia KDIGO targets by two different clinical strategies - a European hemodialysis multicenter analysis.
Drozdz M; Weigert A; Silva F; Frazão J; Alsuwaida A; Krishnan M; Kleophas W; Brzosko S; Johansson FK; Jacobson SH
BMC Nephrol; 2019 Jan; 20(1):5. PubMed ID: 30616548
[TBL] [Abstract][Full Text] [Related]
17. Effects of hypoxia-inducible factor-prolyl hydroxylase inhibitors
Yang J; Xing J; Zhu X; Xie X; Wang L; Zhang X
Front Endocrinol (Lausanne); 2023; 14():1131516. PubMed ID: 37008953
[TBL] [Abstract][Full Text] [Related]
18. Anemia management trends in hospital-based dialysis centers (HBDCs), 2010 to 2013.
Coritsidis GN; Maglinte GA; Acharya A; Saxena A; Chang CL; Hill J; Gitlin M; Lafayette RA
Clin Ther; 2014 Mar; 36(3):408-18. PubMed ID: 24582713
[TBL] [Abstract][Full Text] [Related]
19. The Significance of iron deficiency and anemia in a real-life COPD cohort.
Pizzini A; Aichner M; Sonnweber T; Tancevski I; Weiss G; Löffler-Ragg J
Int J Med Sci; 2020; 17(14):2232-2239. PubMed ID: 32922186
[No Abstract] [Full Text] [Related]
20. Short-term effect of preoperative intravenous iron therapy in colorectal cancer patients with anemia: results of a cohort study.
Wilson MJ; Dekker JW; Bruns E; Borstlap W; Jeekel J; Zwaginga JJ; Schipperus M
Transfusion; 2018 Mar; 58(3):795-803. PubMed ID: 29250797
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
